ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,008
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma
Author(s):
Publication date:
20232022
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
ScienceOpen Research
Data availability:
Comments
Comment on this article
Sign in to comment
Similar content
2,008
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
Authors:
P Paschka
,
H Dombret
,
X. Thomas
…
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.
Authors:
Ghassan K Abou-Alfa
,
Shuchi S Pandya
,
Andrew X Zhu
Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for
IDH1
-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.
Authors:
Christina X. Chamberlain
,
Zhaowei Hua
,
Camelia Gliser
…
See all similar
Cited by
1
Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
Authors:
Adarsh Vardhan Tangella
,
Ashwin Gajre
,
Vivek Varma Kantheti
See all cited by